Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) P/B ratio
As of 16 October 2026, Henry Schein, Inc. (HSIC) trades at a P/B ratio of 2.6×. Over the past ten years it has ranged from 1.8× (March 2020) to 4.1× (June 2017); the current reading is higher than 41% of that period. That is above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 2.3× | 7.59% |
| FY2024 | 2.2× | (5.41%) |
| FY2023 | 2.3× | (13.00%) |
| FY2022 | 2.6× | (1.06%) |
| FY2021 | 2.7× | 11.79% |
| FY2020 | 2.4× | (11.98%) |
| FY2019 | 2.7× | 2.36% |
| FY2018 | 2.7× | (14.69%) |
| FY2017 | 3.1× | (11.84%) |
| FY2016 | 3.5× | (0.89%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 2.5× | 14.85% |
| Mar 2026 | 2.2× | (7.70%) |
| Dec 2025 | 2.3× | 18.10% |
| Sep 2025 | 2.0× | (8.99%) |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| CAH Cardinal Health, Inc. compare | n/m |
| HKPD Cellyan Biotechnology Co., Ltd compare | n/m |
| ACH Accendra Health, Inc. compare | n/m |
| MCK McKesson Corporation compare | n/m |
| FOCL FocalTherics compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | 0.1× |
| COSM Cosmos Health Inc. compare | 1.0× |
| HSIC Henry Schein, Inc. | 2.6× |
| COR Cencora, Inc. compare | 20.3× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on HSIC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement